Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730962 · ClinicalTrials.gov registry record · Phase 2
Interventional Bioremediation of Microbiota in Metabolic Syndrome
A Phase 2 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02730962 is a Phase 2 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 12 participants.
The verdict
NCT02730962, a Phase 2 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether changing the microbial composition in the colon can improve metabolism of sugar in people who are on the verge of developing diabetes (pre-diabetics). Study participants will undergo a fecal microbiota transplantation (FMT) using material from lean donors, as well as a series of tests prior to and after the transplant. The investigators will examine any changes in fecal bacterial composition associated with FMT and determine if any observed changes have an influence on blood sugar metabolism.
Interventions
- OTHER Placebo
- DRUG Vancomycin
- PROCEDURE Fecal Microbiota Transplantation
- DRUG Clindamycin
- DRUG Neomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730962
The ClinicalTrials.gov registry entry for NCT02730962 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02730962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02730962 about?
NCT02730962 is a clinical study titled "Interventional Bioremediation of Microbiota in Metabolic Syndrome". The purpose of this study is to determine whether changing the microbial composition in the colon can improve metabolism of sugar in people who are on the verge of developing diabetes (pre-diabetics). Study participants will undergo a fecal microbiota transplantation (FMT) using material from lean d...
What is the current status of trial NCT02730962?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-06. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02730962?
The interventions under investigation include: Placebo (OTHER), Vancomycin (DRUG), Fecal Microbiota Transplantation (PROCEDURE), Clindamycin (DRUG), Neomycin (DRUG).
Who is sponsoring clinical trial NCT02730962?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.